EC5026 oral tablet
Sponsors
EicOsis Human Health Inc.
Conditions
Chronic Kidney DiseaseDegenerative Disc DiseaseHealthy AdultsHealthy SubjectsNeuropathic PainParkinson's Disease (PD)Spinal Cord InjuriesSpinal Stenosis
Phase 1
Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects
CompletedNCT04908995
Start: 2021-04-30End: 2021-11-24Updated: 2024-02-20
Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy Subjects
CompletedNCT06089837
Start: 2023-11-28End: 2024-05-12Updated: 2025-01-08
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
RecruitingNCT06438471
Start: 2026-05-01End: 2027-12-01Target: 36Updated: 2026-07-10
Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)
RecruitingNCT07142044
Start: 2025-11-01End: 2027-06-01Target: 18Updated: 2026-07-10
Renal Impairment Study for Oral EC5026
RecruitingNCT07694544
Start: 2026-07-01End: 2027-06-30Target: 18Updated: 2026-07-10